PracticeVideosBlogFlashcards

7.4 Cold Chain & Temperature Management

Key Takeaways

  • USP <659> defines storage terms: refrigerator 2-8°C, freezer -25 to -10°C (commonly -20°C), controlled room temperature 20-25°C, cool 8-15°C, warm 30-40°C, excessive heat >40°C

  • USP <1079> provides the good-storage and distribution-practices framework; <659> defines the terms, <1079> defines the practices

  • Most vaccines and biologics are stored at 2-8°C (refrigerator); a few vaccines require freezer storage — read the label each time

  • Temperature is monitored with data loggers, min/max thermometers, and continuous alarm systems; an excursion is investigated, documented, and the manufacturer is contacted for a viability assessment

  • Never refreeze a thawed or warmed product; a cold-chain break raises an integrity question and the product is quarantined like a suspect product until the manufacturer responds

Last updated: September 2026

Scope note: Cold chain and USP <659>/<1079> are not named anywhere in PTCB's official content outline. They are covered here as essential professional background for anyone receiving and storing temperature-sensitive product — not confirmed as directly tested.

Cold chain is the segment of the supply chain that maintains refrigerated or frozen product within a defined temperature range from manufacturer to dispensing. This section covers the USP General Chapter <659> storage-condition terms, the USP <1079> good-storage framework, monitoring practices, and excursion handling — because a cold-chain break turns a viable biologic into a suspect product.

USP <659> Storage Condition Terms

USP General Chapter <659> "Packaging and Storage Requirements" defines the storage condition terms used on drug labels and in pharmacy storage. Know the temperature ranges as working knowledge.

TermTemperature RangeTypical Use
Refrigerator2°C to 8°CMost vaccines, insulin, many biologics
Freezer−25°C to −10°C (commonly −20°C)Some vaccines (e.g., varicella, MMR), certain biologics
Controlled cold temperature2°C to 8°CSynonym range used in some monographs
Controlled room temperature20°C to 25°CMost solid oral dosage forms
Cool8°C to 15°CSome injectables, suppositories
Warm30°C to 40°CRare; specific monographs
Excessive heat>40°CAvoid for nearly all drug products

Vaccines and most biologics are stored at 2°C to 8°C (refrigerator). A few vaccines require freezer storage (−25°C to −10°C, commonly −20°C). The technician must read the label and package insert for each product — "refrigerate" and "freeze" are not interchangeable, and storing a freezer-required vaccine at refrigerator temperatures is as damaging as storing a refrigerated vaccine at freezer temperatures.

USP <1079> Good Storage and Distribution Practices

USP General Chapter <1079> "Good Storage and Distribution Practices for Drug Products" provides the framework for storage, handling, and distribution across the supply chain — including temperature control, monitoring, excursion investigation, and recordkeeping. Where <659> defines the terms, <1079> defines the practices. Together they form the working cold-chain standard for the job, even though PTCB's outline does not name either chapter.

Temperature Monitoring

Cold-chain storage is not "set the fridge and walk away." The technician monitors with:

  • Data loggers — electronic devices that record temperature at intervals and download to software; produce a temperature history for audit
  • Min/max thermometers — show the lowest and highest temperature reached since last reset; require manual reading and reset
  • Continuous monitoring with alarms — alert staff when temperature exits the allowed range

A reading outside 2°C to 8°C for a refrigerated product is an excursion, not automatically a write-off.

Excursion Handling

When a temperature excursion is detected, the technician follows a defined sequence:

  1. Investigate — determine the magnitude and duration of the excursion (data-logger review) and the product(s) affected
  2. Document — record the excursion, the product(s), lot(s), and the time out of range
  3. Quarantine — separate the affected product so it is not dispensed pending a viability decision
  4. Contact the manufacturer — request a stability/viability assessment for the specific product, lot, time, and temperature; the manufacturer's response determines whether the product is returned to stock or wasted
  5. Act on the response — return to stock if cleared with documentation; waste if not, with the wastage record citing the excursion

The manufacturer, not the pharmacy, makes the viability call. The pharmacy documents the call and keeps the response on file.

Never Refreeze

A product that has been frozen and thawed, or a refrigerated product that has warmed, is never refrozen to "restore" cold-chain status. Refreezing does not reverse protein denaturation or potency loss and may further damage the product. A frozen-then-thawed biologic is treated as a suspect product until the manufacturer says otherwise.

Cold-Chain Break → Suspect Product

Under DSCSA, a product whose identity, authenticity, or integrity is in question is a suspect product. A cold-chain break raises a question of integrity (potency may be reduced), so the affected product is quarantined and investigated like any suspect product — with the added step of a manufacturer viability call. If the investigation confirms the product is no longer viable, it may be declared illegitimate and reported via FDA Form 3911 if appropriate, or simply wasted with the excursion documented.

Storage and Receiving

At receiving, a cold-chain shipment must be checked for temperature compliance — a data logger in the box, a temperature indicator, or at minimum a visual check that the coolant is intact. A shipment that arrives warm is quarantined, the wholesaler is notified, and the product is not placed in stock until viability is confirmed. The receiving log ties the cold-chain check to the invoice, so the record of "received in good condition" is contemporaneous and attributable — closing the loop back to the documentation principles in section 7.1.

Monitoring Frequency and Excursion Documentation

A data logger should be read on a defined schedule (e.g., start and end of each shift, or continuously with alarms), and the reading — not just the range — is recorded. A min/max thermometer must be reset after each reading, or the next reading reports the cumulative excursion since the last reset, which understates nothing and overstates nothing but loses the time resolution an investigation needs. The excursion record itself should capture: the product(s) and lot(s), the recorded range and duration, the likely cause (door left open, compressor failure, stock moved during a stockout), the manufacturer contact and case number, and the final disposition. This record is what a board inspector reviews when a cold-chain complaint arrives months later, and it is what ties the excursion to the wastage log if the manufacturer declines viability.

Practical Takeaway

Even though PTCB's outline does not name USP <659>/<1079> specifically, the underlying judgment calls apply broadly: never refreeze a thawed or warmed product, always quarantine and get a manufacturer viability call before returning excursed stock to service, and remember that the manufacturer — not the pharmacy — decides whether an excursed lot is still usable.


USP <659> Storage Condition Midpoint Temperatures (°C)
Test Your Knowledge

According to USP <659>, what is the storage temperature range for a "refrigerator"?

A

−25°C to −10°C

B

2°C to 8°C

C

8°C to 15°C

D

20°C to 25°C

Test Your Knowledge

A data logger shows a refrigerated vaccine held at 11°C for 6 hours overnight. What is the correct first action?

A

Refreeze the vaccine immediately to restore cold-chain status

B

Return the vaccine to stock and record nothing, since 11°C is below room temperature

C

Quarantine the vaccine, document the excursion, and contact the manufacturer for a viability assessment

D

Declare the vaccine illegitimate and file FDA Form 3911 within 24 hours

Sections you finish are checked off in the contents.